Patients' characteristics and treatment administration
NSCLC
LUNG CANCER, DISEASE, NSCLC
A total of 108 patients were entered into this study between June 2013 and March 2019. Patients were recruited at 19 investigational sites of TORG in Japan. The patients' characteristics are listed in Table Patients' background characteristics.Abbreviations: NSCLC, non‐small cell lung cancer; NOS, not otherwise specified; PR, partial response; SD, stable disease.Trial profile.The range of maintenance treatment cycles was 1–24 cycles in the Pgroup and 1–42 cycles in the PBgroup. The median number of treatment cycles of maintenance therapy was 7 in the Pgroup and 8 in the PBgroup. The median and mean relative dose intensities of pemetrexed were 85.7% and 87.3% in the PBgroup and 98.1% and 95% in the Pgroup. The median and mean relative dose intensities of bevacizumab were 85.7% and 84.6% in the PBgroup, respectively.